BioSpace News Archive

InMed Pharmaceuticals Inc. announced that it has entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced the presentation of additional research supporting the differentiation of PVRIG from other immune checkpoint inhibitors.

PYC Therapeutics, a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, released a comprehensive summary of preclinical findings supporting the potential of PYC’s VP-002 program as the first disease modifying therapy for patients suffering from Autosomal Dominant Optic Atrophy.

Anova Enterprises, Inc., an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, and the industry’s first collaborative ‘learning system’, announced a partnership with the NeOnc Technologies, Inc. to accelerate the development of NEO100 for patients with IDH1 mutated gliomas.

4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products, a novel class of drug derived from the microbiome, announces that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer, will present a corporate overview followed by a fireside chat at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 2:30pm ET.

Melinta Therapeutics, LLC, a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Susan Blum as Chief Financial Officer, effective July 1, 2021.

SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies, announced that the first participant has been dosed in its Phase 2a clinical trial evaluating the safety and efficacy of SAB-176 in a human challenge study.

The Phase 1 portion of the ongoing Phase 1/2 study evaluated one- and two-dose regimens of 5µg of eVLP candidate, VBI-2902a, in 61 healthy adults age 18-54 years

Encompass Health Corp. (NYSE: EHC) today announced it will report results for its second quarter ended June 30, 2021 , after the market closes on July 27, 2021 .

Paragonix Technologies, Inc. today announces the launch of its clinical global registry, GUARDIAN-LUNG (Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs).